UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

580 First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.177-178

2012

Volltextzugriff (PDF)

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

Neuro-oncology (Charlottesville, Va.), 2011-01, Vol.13 (1), p.109-118

2011

Volltextzugriff (PDF)

365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour

European journal of cancer supplements, 2010, Vol.8 (7), p.115-116

2010

Volltextzugriff (PDF)

Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation : a study in 136 children

Bone marrow transplantation (Basingstoke), 1992-08, Vol.10 (2), p.135-141

1992

Volltextzugriff (PDF)

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial

Annals of internal medicine, 1997-04, Vol.126 (8), p.600

1997

Volltextzugriff (PDF)

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

EJNMMI research, 2014-09, Vol.4 (1), p.34-34, Article 34

2014

Volltextzugriff (PDF)

An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

European journal of cancer (1990), 1998-06, Vol.34 (7), p.1063-1069

1998

Volltextzugriff (PDF)

Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer

Cancer research (Chicago, Ill.), 1993-02, Vol.53 (3), p.452-455

1993

Volltextzugriff (PDF)

Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation

Bone marrow transplantation (Basingstoke), 1995-12, Vol.16 (6), p.771-775

1995

Volltextzugriff (PDF)

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

EJNMMI research, 2013-09, Vol.3 (1), p.67-67

2013

Volltextzugriff (PDF)

Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma

Bone marrow transplantation (Basingstoke), 1995-10, Vol.16 (4), p.515

1995

Volltextzugriff (PDF)

First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3006-3006

2011

Volltextzugriff (PDF)

Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.6589-6589

2006

Volltextzugriff (PDF)

Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients

Journal of clinical oncology, 2002-01, Vol.20 (1), p.24-36

Viens, P.

2002

Volltextzugriff (PDF)

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent Breast cancer patients

Journal of clinical oncology, 2002, Vol.20 (1), p.24-36

2002

Volltextzugriff (PDF)

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

Journal of clinical oncology, 1993-04, Vol.11 (4), p.630-637

1993

Volltextzugriff (PDF)

In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G‐CSF (rMetHuG‐CSF)

British journal of haematology, 1998-03, Vol.100 (3), p.550-556

1998

Volltextzugriff (PDF)

Protocolisation, use and development of anti-cancer drugs in the context of T2A (case-mix based payment system) set-up

Therapie, 2006-07, Vol.61 (4), p.305-312

2006

Volltextzugriff (PDF)

In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF)

British journal of haematology, 1998-03, Vol.100 (3), p.550-556

1998

Volltextzugriff (PDF)

Solid malignant neoplasms after childhood irradiation: decrease of the relative risk with time after irradiation

Comptes rendus de l'Académie des sciences, Série III, Sciences de la vie, 1995-04, Vol.318 (4), p.483

1995

Volltextzugriff (PDF)

Phase I-II study of interleukin-2 after high-dose chemotherapy and autologour bone marrow transplantation in poorly responding neuroblastoma

Bone marrow transplantation (Basingstoke), 1995, Vol.16 (4), p.515-520

1995

Volltextzugriff (PDF)

Clinical Trials in Paediatric Oncology

Therapie, 2003-05, Vol.58 (3), p.239-246

2003

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

580 First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour

Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation : a study in 136 children

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer

Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma

First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors

Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase

Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent Breast cancer patients

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G‐CSF (rMetHuG‐CSF)

Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial

Protocolisation, Use and Development of Anti-Cancer Drugs in the Context of T2A (Case-Mix Based Payment System) Set-Up

Protocolisation, use and development of anti-cancer drugs in the context of T2A (case-mix based payment system) set-up

In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF)

Protocolisation, utilisation et développement des médicaments anticancéreux dans le cadre de la mise en place de la T2A

Solid malignant neoplasms after childhood irradiation: decrease of the relative risk with time after irradiation

Phase I-II study of interleukin-2 after high-dose chemotherapy and autologour bone marrow transplantation in poorly responding neuroblastoma

Clinical Trials in Paediatric Oncology

Suchergebnisse filtern